PURPOSE: To determine the efficacy and safety of naked plasmid gene therapy to the @entity2687 and epithelium. METHODS: Naked plasmid DNA was injected under pressure into the @entity267 of @entity19 . The expression of genes coding for beta galactosidase (beta-gal), enhanced green fluorescent protein (EGFP), @entity1611 ( @entity1611 ), and soluble @entity9842 (s-Flt) was recorded and measured with regard to dose, time course, and bioactivity. RESULTS: LacZ gene expression of the protein beta-gal was demonstrated as early as 1 hour, with expression persisting for 10 days. Plasmid-injected corneas remained clear and free of @entity32 . EGFP was bicistronically expressed with @entity1611 to demonstrate the practicality of simultaneous in vivo analysis of gene expression and growth factor bioactivity. Corneal injection of a plasmid containing @entity1611 cDNA induced corneal and anterior chamber neovascularization. Moreover, corneal injection of plasmid containing the cDNA for the soluble form of the @entity1611 receptor @entity9842 effectively prevented @entity7499 . CONCLUSIONS: The @entity267 is readily accessible for gene therapy in the laboratory and in the clinic. The method described is safe, effective, titratable, and easily monitored. Naked DNA delivery to the @entity267 has the potential to alter the treatment of a wide variety of corneal and @entity1347 .

Rapid ocular angiogenic control via naked DNA delivery to XXXX .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity267 :: ('MESH:D065306', 'Disease') :: ['cornea'] @entity9842 :: ('14254(Tax:10090)', 'Gene') :: ['Flt-1'] @entity7499 :: ('MESH:D016510', 'Disease') :: ['corneal neovascularization'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity1347 :: ('MESH:C537775', 'Disease') :: ['anterior segment diseases'] @entity2687 :: ('MESH:D003316', 'Disease') :: ['corneal stroma'] @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']
@entity267 :: (MESH:D065306,Disease) :: ['cornea']
